The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.
Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.
NEW YORK – The University of California, Los Angeles, and the Parker Institute for Cancer Immunotherapy (PICI) have renewed a partnership to advance cancer immunotherapy research for ...